Denufosol was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial. A new drug application (NDA)... The drug was also evaluated in the treatment of retinal detachment and other diseases of the retina.
- Mechanism
- Curator reviewed
Denufosol tetrasodium is a selective P2Y2 agonist designed to enhance the lung's innate mucosal hydration and mucociliary clearance mechanisms by activating an alternative ion channel that acts in the same way as the defective ion channel in moving salt and water to the surface of the airways. Based on pre-clinical and clinical work, denufosol has several pharmacological actions contributing to its mechanism of action: hydration of the airways by stimulating chloride and liquid secretions on the epithelial cell surface; inhibition of epithelial sodium absorption; enhancement of ciliary beat frequency; and stimulation of mucin secretion. This unique mechanism of action represents a differentiated approach relative to other approved CF products and may be important in intervening in the early clinical course of CF lung disease.
- Primary indication
- For use as an inhaled treatment for cystic fibrosis.Curator reviewed
- Formula / weight
- C18H27N5O21P4 · 773.323 g/mol (avg)
Resolves to
FPNPSEMJLALQSA-MIYUEGBISA-NSMILES[H]N([H])C1=NC(=O)N(C=C1)[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=CC(=O)N([H])C2=O)O1What you can answer from here — as of September 16, 2026
Which drugs share a target with Denufosol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account